Systemic Sclerosis Clinical Trials

18 recruiting

Frequently Asked Questions

Common questions about Systemic Sclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 41 trials

Recruiting

Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+2 more
Cairo University460 enrolled1 locationNCT07277491
Recruiting
Early Phase 1

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

Sjogren's SyndromeAutoimmune DiseasesIdiopathic Inflammatory Myopathies+3 more
Nanjing Bioheng Biotech Co., Ltd.20 enrolled1 locationNCT06548607
Recruiting
Phase 1Phase 2

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.

Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Beijing GoBroad Hospital45 enrolled1 locationNCT06947473
Recruiting
Phase 1Phase 2

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Beijing GoBroad Hospital45 enrolled1 locationNCT06947460
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Early Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
Changhai Hospital60 enrolled1 locationNCT07246096
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting
Phase 2

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

SclerodermaSystemic Sclerosis (SSc)
Zura Bio Inc80 enrolled51 locationsNCT06843239
Recruiting
Phase 1

A Study of AZD0120 in Autoimmune Diseases

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 1

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathySystemic Sclerosis (SSc)+2 more
Therorna12 enrolled1 locationNCT07413341
Recruiting
Phase 1

DR-0201 in Subjects With Autoimmune Diseases

SclerodermaSLEDermatomyositis+9 more
Dren Bio36 enrolled10 locationsNCT06647069
Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Multiple SclerosisRheumatoid Arthritis (RA)Dermatomyositis+4 more
Kyverna Therapeutics70 enrolled1 locationNCT07403188
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting
Phase 1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094
Recruiting
Phase 1

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955
Recruiting
Phase 2

Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis

Digital Ulcers in Systemic Sclerosis
Topadur Pharma AG15 enrolled5 locationsNCT06954597
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled26 locationsNCT06991114
Recruiting
Phase 1Phase 2

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Systemic Lupus ErythematosusLupusAutoimmune Disorders+2 more
M.D. Anderson Cancer Center47 enrolled2 locationsNCT06434363
Recruiting

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

Solid TumorsSjogren SyndromeImmune-related Adverse Events+3 more
Hospital Universitario Araba300 enrolled1 locationNCT07249060
Recruiting

Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis

Pulmonary HypertensionSystemic Sclerosis (SSc)Systemic Sclerosis-Associated PAH
Alejandro Cruz Utrilla350 enrolled5 locationsNCT07236970